A5037173799- Glioma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Drug Transport and Resistance Mechanisms
- RNA modifications and cancer
- Metal complexes synthesis and properties
- Cancer, Hypoxia, and Metabolism
- Trace Elements in Health
- Immune cells in cancer
- RNA Interference and Gene Delivery
- Medical Imaging Techniques and Applications
- Immunotherapy and Immune Responses
- Mitochondrial Function and Pathology
- Cancer Genomics and Diagnostics
- Synthesis and biological activity
- Nanoparticle-Based Drug Delivery
- HIV/AIDS drug development and treatment
- Metal-Catalyzed Oxygenation Mechanisms
- Histone Deacetylase Inhibitors Research
- PARP inhibition in cancer therapy
- Advanced biosensing and bioanalysis techniques
- Cancer Immunotherapy and Biomarkers
- Reproductive System and Pregnancy
- interferon and immune responses
- Chemokine receptors and signaling
- Synthesis and Characterization of Heterocyclic Compounds
University of Michigan
2021-2025
Ann Arbor Center for Independent Living
2024
Michigan Medicine
2023
Chittaranjan National Cancer Institute
2003-2021
Penn State Milton S. Hershey Medical Center
2021
Cadila Healthcare (India)
2015
Maharaja Sayajirao University of Baroda
2015
Glioblastoma (GBM) is an aggressive primary brain cancer, with a 5 year survival of ∼5%. Challenges that hamper GBM therapeutic efficacy include (i) tumor heterogeneity, (ii) treatment resistance, (iii) immunosuppressive microenvironment (TME), and (iv) the blood-brain barrier (BBB). The C-X-C motif chemokine ligand-12/C-X-C receptor-4 (CXCL12/CXCR4) signaling pathway activated in associated progression. Although CXCR4 antagonist (AMD3100) has been proposed as attractive anti-GBM target, it...
Pediatric high-grade gliomas (pHGGs) are the leading cause of cancer-related deaths in children USA. Sixteen percent hemispheric pediatric and young adult HGGs encode Gly34Arg/Val substitutions histone H3.3 (H3.3-G34R/V). The mechanisms by which H3.3-G34R/V drive malignancy therapeutic resistance pHGGs remain unknown. Using a syngeneic, genetically engineered mouse model (GEMM) human pHGG cells encoding H3.3-G34R, we demonstrate that this mutation led to downregulation DNA repair pathways....
Development of novel strategies to kill cancer by sparing normal cells is utmost importance. Apart from their known antimicrobial activity, only limited information has been recorded regarding the antitumor potential biocompatible silver oxide nanoparticles (AgONPs). There a need evaluate anticancer AgONPs in vitro.A new approach utilizing leaf extract Excoecaria agallocha was used synthesize AgONPs. This then characterized ultraviolet-visible spectrophotometry, nanoparticle-tracking...
Abstract Despite decades of intense research, glioma remains a disease for which no adequate clinical treatment exists. Given the ongoing therapeutic failures conventional approaches, nanomedicine may offer alternative options because it can increase bioavailability drugs and alter their pharmacokinetics. Here, new type synthetic protein nanoparticles (SPNPs) is reported that allow effective loading controlled release potent cancer drug, paclitaxel (PTX) – drug so far has been unsuccessful...
Glioblastoma multiforme (GBM) is highly aggressive primary brain tumor with a 5-year survival rate of 7%. Previous studies have shown that GBM tumors reduced capacity to produce cholesterol and instead depend on the uptake produced by astrocytes. To target metabolism induce cancer cell death, synthetic high-density lipoprotein (sHDL) nanodiscs delivering Liver-X-Receptor (LXR) agonists CpG oligonucleotides for targeting were investigated. LXR synergize sHDL increasing expression ABCA1 are...
Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor with 5-year survival rate of 7%. Previous studies have shown that GBM tumors reduced capacity to produce cholesterol and instead depend on the uptake produced by astrocytes. To target metabolism induce cancer cell death, synthetic high-density lipoprotein (sHDL) nanodiscs delivering Liver-X-Receptor (LXR) agonists CpG oligonucleotides for targeting are investigated. LXR synergize sHDL increasing expression ABCA1 efflux...
Multidrug resistance (MDR) mediated by the over expression of drug efflux protein P-glycoprotein (P-gp) is one major impediments to successful treatment cancer. P-gp acts as an energy-dependent pump and reduces intracellular concentration structurally unrelated drugs inside cells. Therefore, there urgent need for development new molecules that are less toxic normal cell preferentially effective against resistant malignant In this preclinical study we report apoptotic potential copper...
Multiple drug resistance (MDR) remains a major clinical challenge for cancer treatment. P-glycoprotein is the contributor and they exceed their role in chemotherapy of most malignancies. Attempts several preclinical studies to reverse MDR phenomenon by using modulators have not yet generated promising results. In present study, co-ordination complex zinc viz., Zn N-(2-hydroxyacetophenone)glycinate (ZnNG) has been synthesized, characterized its antitumour activity was tested vitro against...
Multidrug resistance (MDR) in cancer represents a variety of strategies employed by tumor cells to evade the beneficial cytotoxic effects structurally different anticancer drugs and thus confers impediments successful treatment cancers. Efflux MDR protein-1, functional P-glycoprotein elevated level reduced glutathione confer cell death or apoptosis provide possible therapeutic target for overcoming cancer. Previously, we reported that Schiff base ligand, potassium-N-(2-hydroxy...
Mutant isocitrate dehydrogenase 1 (mIDH1; IDH1 R132H ) exhibits a gain of function mutation enabling 2-hydroxyglutarate (2HG) production. 2HG inhibits DNA and histone demethylases, inducing epigenetic reprogramming corresponding changes to the transcriptome. We previously demonstrated 2HG-mediated enhances DNA-damage response confers radioresistance in mIDH1 gliomas harboring p53 ATRX loss mutations. In this study, RNA-seq ChIP-seq data revealed human mouse glioma neurospheres have...
Myeloid-derived suppressor cells (MDSCs), one of the major orchestrators immunosuppressive network are present in tumor microenvironment suppress antitumor immunity by subverting Th1 response site and considered as a great obstacle for advancement different cancer immunotherapeutic protocols. Till date, various pharmacological approaches have been explored to modulate suppressive functions MDSCs vivo. The study describes our endeavor explore possibility eradicating application copper...